CLINICAL INVESTIGATION OF EA 1729
Abstract
EA 1729 (lysergic acid diethylamide, LSD25) has been studied extensively in animals and in humans as a possible incapacitating CW compound. Clinical, physiological, and psychiatric studies have been conducted. From the standpoint of biological effectiveness, EA 1729 incapacitates man at doses as low as 1 microgram/kg, the degree of incapacitation increasing with the dose. Its effects endure for periods ranging from 6 to 24 hours. There is a very wide margin of safety between the incapacitating and lethal doses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 1961
- Accession Number
- AD0323701
Entities
People
- Van M. Sim
Organizations
- Edgewood Chemical Biological Center